Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Colorectal Cancer
Interventions
amifostine trihydrate, irinotecan hydrochloride
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
2
States / cities
Los Angeles, California • Rancho Cucamonga, California
Conditions
Liver Transplant Surgery, Colorectal Cancer Metastatic, Colon Cancer Liver Metastases
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
Interventions
Vatalanib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
143
States / cities
Huntsville, Alabama • Anchorage, Alaska • Tucson, Arizona + 113 more
Conditions
Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
Interventions
Labetuzumab Govitecan (LG)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
7
States / cities
Santa Monica, California • Aurora, Colorado • Newark, Delaware + 4 more
Conditions
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Interventions
Topical Dapsone 5% Gel, Moisturizer, oral antibiotics
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Colorectal Neoplasms
Interventions
MEDI6469
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Colorectal Cancer, Head and Neck Cancer, Neoplasm Metastasis
Interventions
BMS-754807, cetuximab (Erbitux®)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Omaha, Nebraska • Durham, North Carolina • Madison, Wisconsin
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
Pembrolizumab, Bevacizumab, Binimetinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer, KRAS G12C, Pancreatic Cancer
Interventions
FMC-376
Drug
Lead sponsor
Frontier Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
La Jolla, California • Orange, California • San Francisco, California + 11 more
Conditions
Metastatic Colorectal Cancer
Interventions
Botensilimab, Balstilimab, Standard of Care
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
26
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 18 more
Conditions
Metastatic Colorectal Carcinoma, Recurrent Colon Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colon Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7
Interventions
Oxaliplatin, Trifluridine and Tipiracil Hydrochloride
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
6
States / cities
Elizabeth, New Jersey • Lakewood, New Jersey • Livingston, New Jersey + 3 more
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFOX regimen, fluorouracil, isolated perfusion, leucovorin calcium, melphalan, oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Advanced Cancers
Interventions
Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Carcinoma of the Appendix, Colorectal Cancer, Primary Peritoneal Cavity Cancer
Interventions
oxaliplatin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
conventional surgery, neoadjuvant therapy, radionuclide imaging, iodine I 131 monoclonal antibody F19
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage II Colon Cancer, Stage II Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Esophageal Cancer, Pancreatic Cancer, Bile Duct Cancer, Gastric Cancer, Gall Bladder Cancer, Small Bowel Adenocarcinoma
Interventions
Bevacizumab, Dasatinib, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
Anne Noonan
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Conditions
Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
Interventions
Pegfilgrastim, Placebo, Bevacizumab, Standard Chemotherapy
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
72
States / cities
Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more
Conditions
Metastatic Colorectal Cancer
Interventions
Futuximab/modotuximab, Trifluridine/Tipiracil
Biological · Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cleveland, Ohio
Conditions
Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Atezolizumab, Bevacizumab, Capecitabine, Laboratory Biomarker Analysis, Placebo
Drug · Biological · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 7 more
Conditions
Colorectal Cancer
Interventions
VS-7375, cetuximab, panitumumab, Cetuximab + mFOLFOX6
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
Los Angeles, California • Tampa, Florida • Indianapolis, Indiana + 10 more
Conditions
Colorectal Neoplasms
Interventions
tucatinib, trastuzumab, bevacizumab, cetuximab, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
132
States / cities
Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 82 more
Recruiting No phase listed Observational

Genomic Services Research Program

NCT02595957
Conditions
Colon Cancer, Breast Cancer
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 105 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2099
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
falimarev, inalimarev, sargramostim, therapeutic autologous dendritic cells
Biological
Lead sponsor
Michael Morse, MD
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Durham, North Carolina + 3 more